# OnCo record indapta-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/indapta-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "indapta-therapeutics" ;
  schema:name "Indapta Therapeutics"@en ;
  schema:description "Indapta Therapeutics, of Houston, makes IDP-023, an off-the-shelf natural killer cell therapy from donor g-NK cells, a subset that lacks the FcR gamma chain, and tests it alongside antibody drugs in myeloma and non-Hodgkin lymphoma and in progressive multiple sclerosis. The FDA granted Fast Track status in 2024, and efficacy data are still early."@en ;
  schema:url <https://onco.cc/companies/indapta-therapeutics/>, <https://indapta.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://indapta.com/>, <https://www.sec.gov/Archives/edgar/data/1910175/000191017525000003/primary_doc.xml>, <https://www.sec.gov/Archives/edgar/data/1910175/000191017522000001/primary_doc.xml> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/dlbcl/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/> ;
  onco:technologies <https://onco.cc/technologies/car-nk-macrophage/>, <https://onco.cc/technologies/allogeneic-cell-therapy/> ;
  onco:trials <https://onco.cc/trials/nct06119685/> .